Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 521

3.

Interaction of insulin-like growth factor II (IGF-II) with multiple plasma proteins: high affinity binding of plasminogen to IGF-II and IGF-binding protein-3.

Oesterreicher S, Blum WF, Schmidt B, Braulke T, Kübler B.

J Biol Chem. 2005 Mar 18;280(11):9994-10000. Epub 2005 Jan 10.

4.

External GTP-bound transglutaminase 2 is a molecular switch for chondrocyte hypertrophic differentiation and calcification.

Johnson KA, Terkeltaub RA.

J Biol Chem. 2005 Apr 15;280(15):15004-12. Epub 2005 Feb 3.

5.

Molecular characterization of covalent complexes between tissue transglutaminase and gliadin peptides.

Fleckenstein B, Qiao SW, Larsen MR, Jung G, Roepstorff P, Sollid LM.

J Biol Chem. 2004 Apr 23;279(17):17607-16. Epub 2004 Jan 27.

6.

Transglutaminase down-regulates the dimerization of epidermal growth factor receptor in rat perivenous and periportal hepatocytes.

Maruko A, Ohtake Y, Katoh S, Ohkubo Y.

Cell Prolif. 2009 Oct;42(5):647-56. doi: 10.1111/j.1365-2184.2009.00622.x. Epub 2009 Jul 9.

PMID:
19614676
7.

Characterization of insulin-like growth factor binding protein-1 kinases from human hepatoma cells.

Ankrapp DP, Jones JI, Clemmons DR.

J Cell Biochem. 1996 Mar 1;60(3):387-99.

PMID:
8867814
8.

Recent advances in understanding the roles of transglutaminase 2 in alcoholic steatohepatitis.

Tatsukawa H, Kojima S.

Cell Biol Int. 2010 Feb 22;34(3):325-34. doi: 10.1042/CBI20090130. Review.

PMID:
20192918
9.

Phosphorylation of transglutaminase 2 by PKA at Ser216 creates 14-3-3 binding sites.

Mishra S, Murphy LJ.

Biochem Biophys Res Commun. 2006 Sep 8;347(4):1166-70. Epub 2006 Jul 17.

PMID:
16870138
11.

Mutation of a critical arginine in the GTP-binding site of transglutaminase 2 disinhibits intracellular cross-linking activity.

Begg GE, Holman SR, Stokes PH, Matthews JM, Graham RM, Iismaa SE.

J Biol Chem. 2006 May 5;281(18):12603-9. Epub 2006 Mar 7.

12.

Purification and characterization of rat brain transglutaminase.

Ohashi H, Itoh Y, Birckbichler PJ, Takeuchi Y.

J Biochem. 1995 Dec;118(6):1271-8.

14.

Substrate preference of transglutaminase 2 revealed by logistic regression analysis and intrinsic disorder examination.

Csosz E, Bagossi P, Nagy Z, Dosztanyi Z, Simon I, Fesus L.

J Mol Biol. 2008 Nov 7;383(2):390-402. doi: 10.1016/j.jmb.2008.08.026. Epub 2008 Aug 22.

PMID:
18761350
16.

Role of N- and C-terminal residues of insulin-like growth factor (IGF)-binding protein-3 in regulating IGF complex formation and receptor activation.

Yan X, Forbes BE, McNeil KA, Baxter RC, Firth SM.

J Biol Chem. 2004 Dec 17;279(51):53232-40. Epub 2004 Oct 12.

17.

Insulin-like growth factor binding protein-3 is secreted as a phosphoprotein by human breast cancer cells.

Pattison ST, Fanayan S, Martin JL.

Mol Cell Endocrinol. 1999 Oct 25;156(1-2):131-9.

PMID:
10612431
18.

Transglutaminase 2 and NF-kappaB interplay during NGF-induced differentiation of neuroblastoma cells.

Condello S, Caccamo D, Currò M, Ferlazzo N, Parisi G, Ientile R.

Brain Res. 2008 May 1;1207:1-8. doi: 10.1016/j.brainres.2008.02.044. Epub 2008 Feb 29.

PMID:
18374307
19.

Tissue transglutaminase-mediated chemoresistance in cancer cells.

Verma A, Mehta K.

Drug Resist Updat. 2007 Aug-Oct;10(4-5):144-51. Epub 2007 Jul 27. Review.

PMID:
17662645
20.

Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis.

Liu T, Tee AE, Porro A, Smith SA, Dwarte T, Liu PY, Iraci N, Sekyere E, Haber M, Norris MD, Diolaiti D, Della Valle G, Perini G, Marshall GM.

Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18682-7. Epub 2007 Nov 14. Erratum in: Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):21021.

Supplemental Content

Support Center